Amanta Healthcare Limited is a fully integrated sterile liquids pharmaceutical manufacturer and marketer focused on Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs), using ABFS and ISBM technologies from a WHO‑GMP certified facility in Gujarat, with a 47-product portfolio, 320 distributors, and exports to 21 countries.

The company is mid-inflection: FY25 revenues were INR275 crore and PAT turned positive to INR11 crore after prior losses, with a historical revenue CAGR of 11.8% (FY21–25); management targets a materially higher 20%+ CAGR over the next two years driven by capacity additions and product mix improvement.

SteriPort®, Amanta’s differentiated two‑port ISBM polypropylene container, is the core revenue driver at ~40–44% of revenues and operates at high utilization (91%), giving the company pricing discipline, perceived sterility advantages over polyethylene containers, and a leadership position in the two‑port IV fluids niche.

Near-term value drivers are capital‑led and operational: a large FY26 capex program (~INR130 crore) to add SteriPort and SVP capacity, plus a 10.8 MW captive solar plant (INR34.8 crore) expected to save ~INR9 crore annually, combined with a conservative FY27 revenue target near INR400 crore and margin expansion to mid‑20s percent EBITDA.

Balance sheet momentum is visible: the company has reduced borrowings and debt‑to‑equity materially from FY23 levels, repaid higher‑coupon instruments, completed an IPO and private placement (INR20 crore), and is prioritizing accelerated deleveraging even while funding expansion.